Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL21P30 (ribosomal protein L21 pseudogene 30) is a processed pseudogene corresponding to the RPL21 gene, which encodes the ribosomal protein L21, a component of the large (60S) subunit of the ribosome[1][4][8][3]. Pseudogenes are genomic DNA sequences similar to normal genes but are non-functional; they have lost their protein-coding ability or are otherwise no longer expressed in the cell[8]. RPL21P30 does not produce a functional protein, is not involved in cellular processes, and is not considered a therapeutic or pharmacological target. It has no known role in disease or biomarker function and is included primarily in genome annotation databases to distinguish functional genes from nonfunctional homologs[1][4][8]. If seeking information about the ribosomal protein itself, refer to "Ribosomal protein L21" (RPL21), not this pseudogene[3][5][1]. Summary note: RPL21P30 is not a therapeutic target and, as a pseudogene, would generally be excluded from most target databases. Its inclusion is likely an error for drug discovery or molecular targeting contexts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L21 pseudogene 30 (RPL21P30).